A Phase 3 interventional study of Epcoritamab and Investigator's Choice Chemotherapy in Diffuse Large B-cell Lymphoma, sponsored by Genmab. Active, not recruiting at 186 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Genmab · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse — 16 open to participants now, 23 under way, 3 of them phase 3. epcoritamab · Lymphoma, Large B-Cell, Diffuse.
Among the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, this one is the 2nd largest by enrollment, is the only one that started in 2021, is one of 3 in phase 3, reaches primary completion later than 0 of the 22 other live ones, and was the 3rd registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →16 of the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse are open now, in 5 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 18+
Hospital Universitario Dr. Jose E. Gonzalez · Sites in Mexico
Ages 18–65
University of Miami · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
By country, each count listing its studies:
epcoritamab: first FDA approval 2023 (EPKINLY), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 17 · Phase 3 3
First in 2020; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 483 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 41 across the 24 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 24 have an industry lead sponsor. The 10 most frequent:
Genmab is the lead sponsor of 72 studies on the registry; 15 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 13 (57%) have results posted.
13 studies in Lymphoma, Large B-Cell, Diffuse by Genmab: none open now, 9 under way, 4 of them phase 3. Of 3 finished, 2 (67%) have results posted.
Among the 13 studies in Lymphoma, Large B-Cell, Diffuse by Genmab, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2021, is one of 4 in phase 3, and was the 4th registered.
Genmab’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 2020.
8 of the studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672705Timothy VoorheesEpcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders | 2026-12-31 |
| NCT05451810GenmabA Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma | 2027-03 |
| NCT06536049Yazeed SawalhaEpcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | 2027-08-31 |
| NCT04542824GenmabTrial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) | 2027-09 |
| NCT07451652Hospital Universitario Dr. Jose E. GonzalezLow Dose Epcoritamab Plus GemOx in R/R DLBCL | 2027-09 |
Add all 8 to your calendar (.ics) → With an account.
Among the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among Genmab’s 13 in Lymphoma, Large B-Cell, Diffuse:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for participants with DLBCL that are not responding to treatment, have grown in size, or have come back following treatment with at least 1 prior systemic cancer therapy. All participants in this trial will be randomly assigned to receive either epcoritamab or a pre-specified investigator's choice (standard of care) chemotherapy (either rituximab + gemcitabine + oxaliplatin [R-GemOx], or bendamustine + rituximab [BR]). Participants must have failed or be ineligible to receive an autologous stem cell transplant (ASCT).
Epcoritamab will be injected under the skin. Investigator's choice chemotherapy will be given intravenously.
Trial details include:
The estimated trial duration for an individual participant depends upon the treatment arm assigned:
Participants who receive investigator's choice (standard of care) chemotherapy will receive treatments either:
The trial is an open label, multi-center, global phase-3 randomized trial of epcoritamab. The goal of this randomized trial is to evaluate the efficacy of epcoritamab (GEN3013, DuoBody®-CD3xCD20) compared to investigator's choice of chemotherapy, in participants with relapsed, refractory DLBCL who have failed or are ineligible for high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT). No change in chemotherapy is permitted for participants during the treatment phase of the trial.
Overall Survival (OS) is the primary endpoint in USA and in China, with the analysis population including all randomized participants. OS/Progression Free Survival (PFS) are dual-primary endpoints for rest of the world (outside US and China), with the analysis population also including all participants randomized.
The China sub-study of GCT3013-05 is registered under NCT07226752.
Main Inclusion Criteria:
One of the confirmed histologies below with CD20-positivity:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Epcoritamab will be administered in Cycles of 28 days until any of the discontinuation criteria is met
Biological: Epcoritamab
R-GemOx will be administrated in Cycles of 28 days until maximum cycles completion or any of the discontinuation criteria is met BR will be administrated in Cycles of 21 days until maximum cycles completion or any of the discontinuation criteria is met
Drug: Investigator's Choice Chemotherapy
Following mandatory pre-medication, participants will be administered epcoritamab as a subcutaneous injection.
Also known as: GEN3013, DuoBody®-CD3xCD20, EPKINLY™
Following mandatory pre-medication, participants will be administered intravenously either BR or R-GemOx.
Also known as: BR or R-GemOx
Overall Survival (OS)
OS was defined as the time from the date of randomization to date of death due to any cause. Participants who were still alive at the clinical cut-off date for the analysis were censored at the last date known to be alive.
Time frame: Up to approximately 4 years, 9 months
| Milestone | Epcoritamab | Investigator's Choice (IC) |
|---|---|---|
| Started | 241 | 242 |
| Received at least 1 dose of trial treatment | 236 | 237 |
| Completed | 0 | 0 |
| Not completed | 241 | 242 |
| Withdrew: Death | 161 | 161 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Withdrawal by subject | 5 | 17 |
| Withdrew: Ongoing in trial | 75 | 62 |
OS was defined as the time from the date of randomization to date of death due to any cause. Participants who were still alive at the clinical cut-off date for the analysis were censored at the last date known to be alive.
| months | Epcoritamab | Investigator's Choice (IC) |
|---|---|---|
| Overall Survival (OS) | 11.3 (7.8 to 15.7) | 10.3 (9.0 to 12.5) |
Collected over Up to approximately 4 years, 9 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epcoritamab | 162/241 (67.2%) | 163/236 (69.1%) | 229/236 (97%) |
| Investigator's Choice (IC) | 169/242 (69.8%) | 77/237 (32.5%) | 224/237 (94.5%) |
| Event | Epcoritamab | Investigator's Choice (IC) |
|---|---|---|
| Cytokine release syndromeImmune system disorders | 62/236 | 0/237 |
| Covid-19Infections and infestations | 44/236 | 15/237 |
| PneumoniaInfections and infestations | 16/236 | 5/237 |
| PyrexiaGeneral disorders and administration site conditions | 12/236 | 1/237 |
| Covid-19 pneumoniaInfections and infestations | 8/236 | 1/237 |
| Urinary tract infectionInfections and infestations | 6/236 | 0/237 |
| Immune effector cell-associated neurotoxicity syndromeNervous system disorders | 6/236 | 0/237 |
| Pneumonia bacterialInfections and infestations | 5/236 | 1/237 |
| Urinary retentionRenal and urinary disorders | 5/236 | 0/237 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/236 | 5/237 |
| Event | Epcoritamab | Investigator's Choice (IC) |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 57/236 | 84/237 |
| Cytokine release syndromeImmune system disorders | 76/236 | 0/237 |
| NauseaGastrointestinal disorders | 32/236 | 73/237 |
| Platelet count decreasedInvestigations | 17/236 | 71/237 |
| NeutropeniaBlood and lymphatic system disorders | 54/236 | 60/237 |
| PyrexiaGeneral disorders and administration site conditions | 55/236 | 30/237 |
| ThrombocytopeniaBlood and lymphatic system disorders | 25/236 | 54/237 |
| Covid-19Infections and infestations | 51/236 | 13/237 |
| Neutrophil count decreasedInvestigations | 30/236 | 49/237 |
| DiarrhoeaGastrointestinal disorders | 46/236 | 29/237 |
Intent-to-Treat (ITT) population included all randomized participants.
| Age, Categorical(Participants) | Epcoritamab | Investigator's Choice (IC) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 56 | 73 | 129 |
| >=65 years | 185 | 169 | 354 |
| Age, Continuous(years) | Epcoritamab | Investigator's Choice (IC) | Total |
|---|---|---|---|
| Mean | 69.9 ± 9.9 | 68 ± 11.8 | 69 ± 10.9 |
| Sex: Female, Male(Participants) | Epcoritamab | Investigator's Choice (IC) | Total |
|---|---|---|---|
| Female | 110 | 100 | 210 |
| Male | 131 | 142 | 273 |
| Race/Ethnicity, Customized(Participants) | Epcoritamab | Investigator's Choice (IC) | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 9 | 20 |
| Not Hispanic or Latino | 187 | 193 | 380 |
| Unknown | 43 | 40 | 83 |
| Race/Ethnicity, Customized(Participants) | Epcoritamab | Investigator's Choice (IC) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 55 | 74 | 129 |
| Black or African American | 1 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Not Reported | 44 | 38 | 82 |
| Other | 0 | 0 | 0 |
| Unknown | 0 | 1 | 1 |
| White | 141 | 126 | 267 |
| Region of Enrollment(Participants) | Epcoritamab | Investigator's Choice (IC) | Total |
|---|---|---|---|
| Australia | 7 | 5 | 12 |
| Austria | 1 | 2 | 3 |
| Belgium | 14 | 17 | 31 |
| Canada | 1 | 3 | 4 |
| Denmark | 7 | 4 | 11 |
| Finland | 4 | 1 | 5 |
| France | 37 | 33 | 70 |
| Germany | 5 | 4 | 9 |
| Hungary | 11 | 9 | 20 |
| Israel | 3 | 1 | 4 |
| Italy | 14 | 11 | 25 |
| Japan | 23 | 42 | 65 |
| South Korea | 19 | 17 | 36 |
| Netherlands | 2 | 8 | 10 |
| Norway | 7 | 3 | 10 |
| Poland | 10 | 7 | 17 |
| Russia | 2 | 5 | 7 |
| Singapore | 4 | 7 | 11 |
| Spain | 20 | 20 | 40 |
| Sweden | 1 | 1 | 2 |
| Taiwan | 8 | 7 | 15 |
| Turkey | 20 | 18 | 38 |
| United Kingdom | 16 | 13 | 29 |
| United States | 5 | 4 | 9 |
Showing the first 100 of 186 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2021 to primary completion in Oct 2025, 57 months.
Results were first posted in Nov 2026, 1 year after primary completion.
Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's 57 months is close to that.
Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epcoritamab
Lymphoma, Large B-Cell, Diffuse →